

Thorsten Langer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8021983/publications.pdf>

Version: 2024-02-01

29
papers

540
citations

932766

10
h-index

642321

23
g-index

30
all docs

30
docs citations

30
times ranked

884
citing authors

#	ARTICLE	IF	CITATIONS
1	Parents' Perspectives on Diagnosis and Decision-Making regarding Ventilator Support in Children with SMA Type 1. <i>Neuropediatrics</i> , 2022, 53, 122-128.	0.3	3
2	Overcoming language barriers, enhancing collaboration with interpreters – an interprofessional learning intervention (Interpret2Improve). <i>BMC Medical Education</i> , 2022, 22, 170.	1.0	4
3	De novo truncating <i>NOVA2</i> variants affect alternative splicing and lead to heterogeneous neurodevelopmental phenotypes. <i>Human Mutation</i> , 2022, 43, 1299-1313.	1.1	6
4	Interprofessional perceptions of emotional, social, and ethical effects of multidrug-resistant organisms: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0246820.	1.1	4
5	Postdural puncture headache – a single-centre analysis in paediatric patients with and without SMA. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 1895-1901.	0.7	0
6	Spasmodic Abdominal Pain and Other Gastrointestinal Symptoms in Pontocerebellar Hypoplasia Type 2. <i>Neuropediatrics</i> , 2021, 52, 495-498.	0.3	0
7	Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy – Protocol of a Controlled Mixed-Methods Study. <i>Frontiers in Pediatrics</i> , 2021, 9, 614512.	0.9	5
8	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. <i>Pharmacogenomics Journal</i> , 2020, 20, 294-305.	0.9	28
9	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. <i>European Journal of Cancer</i> , 2020, 138, 212-224.	1.3	31
10	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. <i>Data in Brief</i> , 2020, 32, 106227.	0.5	2
11	Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 194.	1.2	12
12	Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. <i>Acta Myologica</i> , 2020, 39, 2-12.	1.5	5
13	Decision-Making Regarding Ventilator Support in Children with SMA Type 1 – A Cross-Sectional Survey among Physicians. <i>Neuropediatrics</i> , 2019, 50, 359-366.	0.3	4
14	Interprofessional perceptions and emotional impact of multidrug-resistant organisms: A qualitative study. <i>American Journal of Infection Control</i> , 2019, 47, 876-882.	1.1	10
15	Discrepancy in redetermination of <i>SMN2</i> copy numbers in children with SMA. <i>Neurology</i> , 2019, 93, 267-269.	1.5	43
16	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. <i>JMIR Research Protocols</i> , 2019, 8, e11868.	0.5	10
17	Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 122-127.	0.7	31
18	Navigating Communication Challenges in Clinical Practice: A New Approach to Team Education. <i>Critical Care Nurse</i> , 2018, 38, 15-22.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 135-143.	1.1	97
20	FV 953. Parents' Experiences during the Compassionate Use Program (Nusinersen) for Patients with Spinal Muscular Atrophy Type 1 – A Qualitative Interview Study. , 2018, 49, .		0
21	P 900. Decision Making Regarding Ventilator Support in Children with SMA type 1 – A Cross-sectional Survey among German Physicians. , 2018, 49, .		0
22	FV 880. Disorders of Coagulation in Duchenne Muscular Dystrophy? – Results of a Registry-Based Online Questionnaire. <i>Neuropediatrics</i> , 2018, 49, .	0.3	0
23	Outcomes in Duchenne muscular dystrophy: nature, nurture, culture – or all three?. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 780-781.	1.1	2
24	Barriers and Bridges. <i>Academic Pediatrics</i> , 2016, 16, 501-502.	1.0	0
25	A longitudinal, randomized, and prospective study of nocturnal monitoring in children and adolescents with epilepsy: Effects on quality of life and sleep. <i>Epilepsy and Behavior</i> , 2016, 61, 192-198.	0.9	13
26	Patients and families as teachers: a mixed methods assessment of a collaborative learning model for medical error disclosure and prevention. <i>BMJ Quality and Safety</i> , 2016, 25, 615-625.	1.8	31
27	Medical Students' Development of Ethical Judgment - Exploring the Learners' Perspectives using a mixed methods approach. <i>GMS Journal for Medical Education</i> , 2016, 33, Doc74.	0.1	3
28	Prevalence of Epileptiform Discharges in Healthy Infants. <i>Journal of Child Neurology</i> , 2015, 30, 1409-1413.	0.7	5
29	Understanding platinum-induced ototoxicity. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 458-469.	4.0	183